Проблема гендерної рівності в науці: досягнення та виклики (Problem of gender equality in science: achievements and challenges)

У статті проаналізовано заходи, спрямовані на впровадження гендерної рівності в науковій галузі з метою повнішого використання інтелектуального потенціалу жінок-учених. Підсумовано основні досягнення на цьому шляху, визначено напрямки, на яких необхідно зосередити подальші зусилля як у сфері наукових досліджень, так і в управлінській науковій і соціальній сферах. Наголошено на важливості досвіду західних країн з гендерної політики для України. На підставі результатів аналізу участі обох гендерних груп науковців у програмах Державного фонду фундаментальних досліджень за 2015 р, обґрунтовано необхідність підвищення наукової активності українських жінок-вчених. (The measures for the implementation of gender equality in the scientific sector to more fully use the intellectual potential of women scientists were analysed. The main achievements in this direction were summed up, and the directions in which it is necessary to focus further efforts both in research and in management science and social spheres were identified. For several decades it was carried out a large number of measures to more fully explore the possibilities of using the intellectual potential of the female half of humanity and gender equality in science, which is the main area of implementation of educational knowledge and which progress provides economic and social development of society. An increase in the participation of women in all fields of scientific research, and the average attainment of the degree of Doctor of Philosophy confidently approaching gender parity as in 28 countries of the European Union, US and Canada; significant progress over the last two decades reached also in attracting women to the fields of Science, Physics and Mathematics profile, such as geological, engineering, computer science, economics, chemistry and physics. It was found that the inclusion of the gender dimension in the process of acquiring knowledge changes their quality, efficiency and structure of research and, therefore science is not gender neutral. The new strategy documents for the EU 2016-2019 years stressed that the issue of gender equality remains important in all areas of modern politics of this structure. In the field of research and innovation policy it is planned to solve this problem by supporting the program «Horizon – 2020» through cooperation and research organizations of member countries within the European Research Area. This identified three focus areas, namely gender equality in scientific careers, gender balance in decision-making and the integration of gender approach in research and innovation

Impaired CD8+ T-Cell Reactivity against Viral Antigens in Cancer Patients with Solid Tumors

Background: : Patients with hematological malignancies are at increased risk for various infections. In patients with solid cancer, a variety of immunosuppressive mechanisms affecting T-cell response are described. We hypothesized that patients with advanced solid tumors may exhibit an impaired recognition of viral antigens. To test this, the capability of CD8+ T cells to recognize recall antigens from influenza and vaccinia virus was compared in patients and healthy individuals. Since all patients and most of the healthy individuals had been vaccinated against vaccinia years ago, comparison of the two groups was expected to be especially informative with respect to distinct effector T-cell reactivity. Materials and Methods: : Our test population included 16 healthy individuals and 12 patients with advanced solid cancers who were currently not receiving chemotherapy. We stimulated peripheral blood mononuclear cells (PBMC) ex vivo with the well-characterized influenza A matrix 58-66 peptide and the immunogenic and HLA-A*0201 restricted peptide epitope SLSAYIIRV derived from the modified vaccinia virus Ankara (MVA). A specific CD8+ T-cell reactivity was determined by quantitative real-time polymerase chain reaction (qRT-PCR) measuring changes in interferon gamma (IFN-γ) mRNA expression levels. Results: : We found that significantly fewer cancer patients than healthy individuals exhibited specific T-cell recognition of the vaccinia epitope (25% and 69%, respectively). In addition, strength of the T-cell responses against both viral peptides was significantly reduced in cancer patients. Conclusion: : Patients with advanced tumors are less likely to mount a T-cell response against viral epitopes. These findings may have implications for the design of immunotherapeutic interventions against virus-induced diseases, including tumor

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC. Aim of this research was to study the prognostic and predictive value of tumor (MET, the receptor tyrosine kinase encoded by the homonymous MNNG-HOS transforming gene) and circulating (MET, hepatocyte growth factor [HGF], alpha-fetoprotein [AFP], vascular endothelial growth factor [VEGF]) biomarkers in second-line HCC. Tumor MET-High status was centrally assessed by immunohistochemistry. Circulating biomarkers were centrally analyzed on serum samples collected at baseline and every 4-8 weeks, using medians as cut-off to determine High/Low status. Tumor MET, tested in 77 patients, was more frequently High after (82%) versus before (40%) sorafenib. A significant interaction (p = 0.04) between tivantinib and baseline tumor MET in terms of survival was observed. Baseline circulating MET and HGF (102 patients) High status correlated with shorter survival (HR 0.61, p = 0.03, and HR 0.60, p = 0.02, respectively), while the association between AFP (104 patients) or VEGF (103 patients) status and survival was non-significant. Conclusions: Tumor MET levels were higher in patients treated with sorafenib. Circulating biomarkers such as MET and HGF may be prognostic in second-line HCC. These results need to be confirmed in larger randomized clinical trials

Barkhausen noise emission of AISI 304 stainless steel originating from strain induced martensite by shot peening

This study deals with magnetic Barkhausen noise emission produced by strain-induced martensite generated during shot peening of austenitic AISI 304 stainless steel. The transformation from the paramagnetic to ferromagnetic state and the corresponding birth of the magnetic domain structure are important with respect to irreversible motion of domain walls and the corresponding Barkhausen noise emission. Barkhausen noise is investigated and explained with respect to the residual stress state as well as the micro-structure expressed in terms of the martensite fraction, its crystallite size, preferred orientation, surface topography, and microhardness. The strength of the Barkhausen noise is mainly linked with the number of shot peening cycles, corresponding Almen intensity, and the associated volume fraction of strain-induced martensite as well as the extent of its depth. The role of the residual stress state in the martensite phase is minor. Surface strengthening expressed in terms of the microhardness in the near-surface region is very high for the medium shot peening intensity. A remarkable decrease in the near-surface microhardness as well as the presence of heavily thinned folds indicate over shot peen-ing and surface microcracking in the case of a longer shot peening time and the corre-sponding higher Almen intensity.Web of Science2076274

Mindfulness based interventions in multiple sclerosis: a systematic review

<b>Background</b> Multiple sclerosis (MS) is a stressful condition; depression, anxiety, pain and fatigue are all common problems. Mindfulness based interventions (MBIs) mitigate stress and prevent relapse in depression and are increasingly being used in healthcare. However, there are currently no systematic reviews of MBIs in people with MS. This review aims to evaluate the effectiveness of MBIs in people with MS.<p></p> <b>Methods</b> Systematic searches were carried out in seven major databases, using both subject headings and key words. Papers were screened, data extracted, quality appraised, and analysed by two reviewers independently, using predefined criteria. Study quality was assessed using the Cochrane Collaboration risk of bias tool. Perceived stress was the primary outcome. Secondary outcomes include mental health, physical health, quality of life, and health service utilisation. Statistical meta-analysis was not possible. Disagreements were adjudicated by a third party reviewer.<p></p> <b>Results</b> Three studies (n = 183 participants) were included in the final analysis. The studies were undertaken in Wales (n = 16, randomised controlled trial - (RCT)), Switzerland (n = 150, RCT), and the United States (n = 17, controlled trial). 146 (80%) participants were female; mean age (SD) was 48.6 (9.4) years. Relapsing remitting MS was the main diagnostic category (n = 123, 67%); 43 (26%) had secondary progressive disease; and the remainder were unspecified. MBIs lasted 6–8 weeks; attrition rates were variable (5-43%); all employed pre- post- measures; two had longer follow up; one at 3, and one at 6 months. Socio-economic status of participants was not made explicit; health service utilisation and costs were not reported. No study reported on perceived stress. All studies reported quality of life (QOL), mental health (anxiety and depression), physical (fatigue, standing balance, pain), and psychosocial measures. Statistically significant beneficial effects relating to QOL, mental health, and selected physical health measures were sustained at 3- and 6- month follow up.<p></p> <b>Conclusion</b> From the limited data available, MBIs may benefit some MS patients in terms of QOL, mental health, and some physical health measures. Further studies are needed to clarify how MBIs might best serve the MS population.<p></p&gt

Expressive and Instrumental Offending: Reconciling the Paradox of Specialisation and Versatility

Although previous research into specialisation has been dominated by the debate over the existence of specialisation versus versatility, it is suggested that research needs to move beyond the restrictions of this dispute. The current study explores the criminal careers of 200 offenders based on their criminal records, obtained from a police database in the North West of England, aiming to understand the patterns and nature of specialisation by determining the presence of differentiation within their general offending behaviours and examining whether the framework of Expressive and Instrumental offending styles can account for any specialised tendencies that emerge. Fifty-eight offences were subjected to Smallest Space Analysis. Results revealed that a model of criminal differentiation could be identified and that any specialisation is represented in terms of Expressive and Instrumental offending styles

Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score

Background: Allocation of patients with hepatocellular carcinoma (HCC) to the adequate therapy is determined by both tumor burden and liver function. The Barcelona Clinic Liver Cancer (BCLC) staging system and therapeutic algorithm recommends transarterial chemoembolization (TACE) based on the best evidence available to patients with intermediate-stage HCC (BCLC-B). However, many centers also treat subgroups of patients outside these recommendations and with more advanced disease by TACE. The purpose of this study was to identify prognostic factors in a TACE cohort, including BCLC-B patients, as well as patients treated outside of BCLC-B, to test the prognostic capabilities of published staging systems and to optimize prognostication for TACE patients.Patients and Methods: A cohort of 186 first-line TACE patients was analyzed. Independent prognostic factors were identified and used to construct the Munich-TACE score (M-TACE). M-TACE was tested against established staging systems (including BCLC and two recently published TACE-specific scores) and a ranking using concordance index and Akaike Information Criterion was performed. Finally, an external validation in an independent TACE cohort (n=71) was conducted.Results: Bilirubin, Quick/international normalized ratio, C-reactive protein, creatinine, -feto protein, and tumor extension were identified as independent prognostic factors and used to construct M-TACE. M-TACE identifies three distinct subgroups (P<0.0001) with median survival times of 35.2, 16.9, and 8.6 months, respectively. Compared with established staging systems, M-TACE showed the best prognostic capabilities in both cohorts of patients (cohort 1: c-index, 0.71;Akaike Information Criterion: 1276;cohort 2: c-index, 0.754).Conclusion: We identified independent risk factors for patients treated with TACE. The newly constructed M-TACE score is superior to established staging systems and might prove helpful to identify patients who are most suitable for TACE

Genetic and epigenetic analyses of MBD3 in colon and lung cancer

MBD3: is a member of the methyl-CpG-binding domain family and is located on chromosome 19p13.3, a region of loss of heterozygosity in colon and lung cancers. We therefore screened samples for abnormalities in MBD3. Our results indicate that MBD3 is not a major target of genetic and epigenetic alteration in these cancers.Publisher PDFPeer reviewe